{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:14:34Z","timestamp":1787904874222,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.10.075","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T12:57:08Z","timestamp":1603889828000},"page":"633-640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group"],"prefix":"10.1016","volume":"39","author":[{"given":"Euzebiusz","family":"Jamrozik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Littler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3656-564X","authenticated-orcid":false,"given":"Gagandeep","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0321-7128","authenticated-orcid":false,"given":"Melissa","family":"Kapulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-0557","authenticated-orcid":false,"given":"Ross","family":"Upshur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Weijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Selgelid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.10.075_b0005","unstructured":"WHO Director-General. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19: 11 March 2020. Geneva: World Health Organization; 2020 (https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020, accessed 3 May 2020)."},{"key":"10.1016\/j.vaccine.2020.10.075_b0010","unstructured":"COVID-19: potential impact on the world\u2019s poorest people. Rome: World Food Programme; 2020."},{"key":"10.1016\/j.vaccine.2020.10.075_b0015","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMp2003762","article-title":"Responding to Covid-19: a once-in-a-century pandemic?","volume":"382","author":"Gates","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.075_b0020","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJMp2002125","article-title":"Defining the epidemiology of Covid-19: studies needed","volume":"382","author":"Lipsitch","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.075_b0025","doi-asserted-by":"crossref","unstructured":"Jamrozik E, Selgelid MJ. Human challenge studies in endemic settings: ethical and regulatory issues. SpringerBriefs in Ethics; 2020.","DOI":"10.1007\/978-3-030-41480-1"},{"key":"10.1016\/j.vaccine.2020.10.075_b0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fmed.2018.00297","article-title":"Controlled human infections as a tool to reduce uncertainty in clinical vaccine development","volume":"5","author":"Roestenberg","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.vaccine.2020.10.075_b0035","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3568981","article-title":"Covid-19 vaccine development: time to consider Sars-Cov-2 challenge studies?","author":"Schaefer","year":"2020","journal-title":"SSRN Electronic J"},{"issue":"24","key":"10.1016\/j.vaccine.2020.10.075_b0040","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1016\/j.vaccine.2020.04.039","article-title":"Extraordinary diseases require extraordinary solutions","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.075_b0045","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa152","article-title":"Human challenge studies to accelerate coronavirus vaccine licensure","author":"Eyal","year":"2020","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.075_b0050","doi-asserted-by":"crossref","first-page":"e00417","DOI":"10.1128\/mBio.00417-16","article-title":"Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model","volume":"7","author":"Memoli","year":"2016","journal-title":"MBio"},{"issue":"10","key":"10.1016\/j.vaccine.2020.10.075_b0055","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1016\/S1473-3099(18)30177-4","article-title":"Experimental infection of human volunteers","volume":"18","author":"Roestenberg","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.075_b0060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"10111","key":"10.1016\/j.vaccine.2020.10.075_b0065","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2020.10.075_b0070","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1128\/IAI.67.12.6341-6345.1999","article-title":"Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination","volume":"67","author":"Tacket","year":"1999","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.075_b0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/jme.2003.004440","article-title":"Challenge studies of human volunteers: ethical issues","volume":"30","author":"Hope","year":"2004","journal-title":"J Med Ethics"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.075_b0080","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1086\/322664","article-title":"The ethical challenge of infection-inducing challenge experiments","volume":"33","author":"Miller","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.075_b0085","first-page":"1","article-title":"When could human challenge trials be deployed to combat emerging infectious diseases? Lessons from the case of a Zika virus human challenge trial","volume":"20","author":"Palacios","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.vaccine.2020.10.075_b0090","unstructured":"Shah SK, Kimmelman J, Lyerly AD, Lynch HF, McCutchan F, Miller FG et al. Ethical considerations for Zika virus human challenge trials. National Institute of Allergy and Infectious Diseases; 2017."},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.075_b0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/phe\/phv026","article-title":"Ethical criteria for human challenge studies in infectious diseases","volume":"9","author":"Bambery","year":"2015","journal-title":"Public Health Ethics"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.075_b0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bioe.12736","article-title":"What risks should be permissible in controlled human infection model studies?","volume":"34","author":"Binik","year":"2020","journal-title":"Bioethics"},{"key":"10.1016\/j.vaccine.2020.10.075_b0105","doi-asserted-by":"crossref","DOI":"10.1111\/bioe.12802","article-title":"Ethical issues surrounding controlled human infection challenge studies in endemic low-and middle-income countries","author":"Jamrozik","year":"2020","journal-title":"Bioethics"},{"key":"10.1016\/j.vaccine.2020.10.075_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.vaccine.2020.10.075_b0115","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2005630","article-title":"Developing COVID-19 vaccines at pandemic speed","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.075_b0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fmed.2018.00297","article-title":"Dealing with uncertainty in vaccine development: the malaria case","volume":"5","author":"Roestenberg","year":"2018","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.vaccine.2020.10.075_b0125","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2018.12.040","article-title":"Demonstrating vaccine effectiveness during a waning epidemic: a WHO\/NIH meeting report on approaches to development and licensure of Zika vaccine candidates","volume":"37","author":"Vannice","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.075_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","author":"Verity","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.075_b0135","unstructured":"Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. Geneva: World Health Organization; 2020."},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.075_b0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/1475-2875-8-277","article-title":"Cardiac complication after experimental human malaria infection: a case report","volume":"8","author":"Nieman","year":"2009","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2020.10.075_b0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fcimb.2019.00107","article-title":"The future of flu: a review of the human challenge model and systems biology for advancement of influenza vaccinology","volume":"9","author":"Sherman","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2020.10.075_b0150","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1076","article-title":"Responding to the COVID-19 pandemic: ethical considerations for conducting controlled human infection studies","author":"Shah","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.vaccine.2020.10.075_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30438-2","article-title":"Covid-19 human challenge studies: ethical issues","volume":"20","author":"Jamrozik","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.075_b0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hast.1034","article-title":"Clinical trial portfolios: a critical oversight in human research ethics, drug regulation, and policy","volume":"49","author":"London","year":"2019","journal-title":"Hastings Cent Rep"},{"key":"10.1016\/j.vaccine.2020.10.075_b0165","unstructured":"Research in global health emergencies: ethical issues. Nuffield Council on Bioethics; 2020."},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.075_b0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/phe\/phx021","article-title":"Influenza vaccination strategies should target children","volume":"11","author":"Bambery","year":"2018","journal-title":"Public Health Ethics"},{"key":"10.1016\/j.vaccine.2020.10.075_b0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.12688\/wellcomeopenres.14439.1","article-title":"Ethical considerations in controlled human malaria infection studies in low resource settings: experiences and perceptions of study participants in a malaria challenge study in Kenya","volume":"3","author":"Njue","year":"2018","journal-title":"Wellcome Open Res"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.075_b0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1556264618820219","article-title":"Exploring ethical concerns about human challenge studies: a qualitative study of controlled human malaria infection study participants\u2019 motivations and attitudes","volume":"14","author":"Kraft","year":"2019","journal-title":"J Empirical Res Human Res Ethics"},{"key":"10.1016\/j.vaccine.2020.10.075_b0185","series-title":"Ebola\u2019s message: public health and medicine in the twenty-first century","article-title":"The use and study of unregistered Ebola interventions: ethics and equipoise","author":"Selgelid","year":"2016"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.075_b0190","first-page":"263","article-title":"Ethical challenges posed by human infection challenge studies in endemic settings","volume":"3","author":"Selgelid","year":"2018","journal-title":"Indian J Medical Ethics"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.075_b0195","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/jme.2008.026062","article-title":"Limits to research risks","volume":"35","author":"Miller","year":"2009","journal-title":"J Med Ethics"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.075_b0200","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12936-015-0671-x","article-title":"Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya","volume":"14","author":"Hodgson","year":"2015","journal-title":"Malar J"},{"issue":"6385","key":"10.1016\/j.vaccine.2020.10.075_b0205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1126\/science.aaq0917","article-title":"Bystander risk, social value, and ethics of human research","volume":"360","author":"Shah","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.10.075_b9000","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS-CoV-2 in France","author":"Salje","year":"2020","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:14Z","timestamp":1759402334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20313955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20313955"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}